title: Sulfonylureas suppress the stimulatory action of Mg-nucleotides on Kir6.2/SUR1 but not Kir6.2/SUR2A KATP channels: a mechanistic study.
abstract: Sulfonylureas, which stimulate insulin secretion from pancreatic β-cells, are widely used to treat both type 2 diabetes and neonatal diabetes. These drugs mediate their effects by binding to the sulfonylurea receptor subunit (SUR) of the ATP-sensitive K(+) (KATP) channel and inducing channel closure. The mechanism of channel inhibition is unusually complex. First, sulfonylureas act as partial antagonists of channel activity, and second, their effect is modulated by MgADP. We analyzed the molecular basis of the interactions between the sulfonylurea gliclazide and Mg-nucleotides on β-cell and cardiac types of KATP channel (Kir6.2/SUR1 and Kir6.2/SUR2A, respectively) heterologously expressed in Xenopus laevis oocytes. The SUR2A-Y1206S mutation was used to confer gliclazide sensitivity on SUR2A. We found that both MgATP and MgADP increased gliclazide inhibition of Kir6.2/SUR1 channels and reduced inhibition of Kir6.2/SUR2A-Y1206S. The latter effect can be attributed to stabilization of the cardiac channel open state by Mg-nucleotides. Using a Kir6.2 mutation that renders the KATP channel insensitive to nucleotide inhibition (Kir6.2-G334D), we showed that gliclazide abolishes the stimulatory effects of MgADP and MgATP on β-cell KATP channels. Detailed analysis suggests that the drug both reduces nucleotide binding to SUR1 and impairs the efficacy with which nucleotide binding is translated into pore opening. Mutation of one (or both) of the Walker A lysines in the catalytic site of the nucleotide-binding domains of SUR1 may have a similar effect to gliclazide on MgADP binding and transduction, but it does not appear to impair MgATP binding. Our results have implications for the therapeutic use of sulfonylureas.
authors.affiliation: Oxford Centre for Gene Function and Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford OX1 3PT, England, UK Oxford Centre for Gene Function and Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford OX1 3PT, England, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Proks
authors.affiliation: Oxford Centre for Gene Function and Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford OX1 3PT, England, UK Oxford Centre for Gene Function and Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford OX1 3PT, England, UK.
authors.forename: Heidi
authors.initials: H
authors.lastname: de Wet
authors.affiliation: Oxford Centre for Gene Function and Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford OX1 3PT, England, UK Oxford Centre for Gene Function and Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford OX1 3PT, England, UK frances.ashcroft@dpag.ox.ac.uk.
authors.forename: Frances M
authors.initials: FM
authors.lastname: Ashcroft
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000494:pharmacology*; D020816:Amino Acid Motifs; D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D002478:Cells, Cultured; D005907:Gliclazide / Q000494:pharmacology*; D006801:Humans; D050417:Insulin-Secreting Cells / Q000378:metabolism; D015640:Ion Channel Gating; D008969:Molecular Sequence Data; D024661:Potassium Channels, Inwardly Rectifying / Q000737:chemistry / Q000378:metabolism*; D011485:Protein Binding; D051381:Rats; D064233:Sulfonylurea Receptors / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D014981:Xenopus; D000099161:Kcnj11 Channel
chemical_list: D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D005907:Gliclazide; D024661:Potassium Channels, Inwardly Rectifying; D064233:Sulfonylurea Receptors; D000099161:Kcnj11 Channel; C577509:Abcc8 protein, rat; C577512:Abcc9 protein, rat